Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Chmp symbols : Bmy save search
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
Published: 2024-01-26 (Crawled : 15:30) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.71%
H: 0.48%
C: -0.52%
chmp positive cell therapy
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Published: 2023-11-10 (Crawled : 12:30) - prnewswire.com
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.4%
H: 0.18%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
krasg12 lung chmp positive cancer cell treatment therapeutics
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
Published: 2023-07-21 (Crawled : 12:20) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.19%
H: 1.41%
C: 1.24%
melanoma chmp opdivo approval positive treatment
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia
Published: 2023-01-27 (Crawled : 13:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.0%
H: 0.63%
C: -0.74%
reblozyl chmp positive
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Published: 2023-01-27 (Crawled : 13:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.0%
H: 0.63%
C: -0.74%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -0.0%
H: 0.25%
C: -0.48%
treatment chmp psoriasis positive
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma
Published: 2022-07-22 (Crawled : 12:20) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.29%
H: 0.49%
C: -0.41%
treatment melanoma antibody chmp approval positive nivolumab
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
TAK | News | $13.16 0.08% 0.53% 1.2M
|
Health Technology
|
| O: -0.53%
H: 0.57%
C: 0.34%
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 1.21%
H: 0.0%
C: 0.0%
EXEL | $22.49 -1.66% -1.78% 2.1M
|
Health Technology
|
| O: 0.14%
H: 1.53%
C: 1.48%
cabometyx positive cancer chmp
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab)
Published: 2022-02-25 (Crawled : 13:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
opdivo positive chmp nivolumab
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B
Published: 2022-01-28 (Crawled : 13:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: -0.28%
H: 1.95%
C: 1.93%
cel positive therapy chmp t-cell
Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
Published: 2021-10-15 (Crawled : 14:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.71%
H: 1.0%
C: 0.43%
treatment positive chmp ulcerative colitis
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction
Published: 2021-09-17 (Crawled : 13:15) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: -1.14%
H: 0.0%
C: 0.0%
positive therapy chmp her2+ her2- her2 nivolumab
Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma
Published: 2021-06-25 (Crawled : 12:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.12%
H: 1.76%
C: 1.23%
positive therapy chmp car-t t-cell
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
Published: 2021-06-25 (Crawled : 12:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.12%
H: 1.76%
C: 1.23%
disease treatment positive therapy cancer iot chmp nivolumab
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient
Published: 2021-05-21 (Crawled : 23:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.36%
H: 1.01%
C: -0.28%
treatment positive chmp nivolumab
Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
Published: 2021-04-23 (Crawled : 12:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: -0.03%
H: 0.95%
C: -0.44%
myeloid leukemia positive therapy leukemia chmp acute myeloid leukemia
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
Published: 2021-04-23 (Crawled : 11:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: -0.03%
H: 0.95%
C: -0.44%
treatment positive approval chmp nivolumab
Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
Published: 2020-12-11 (Crawled : 15:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.22%
H: 1.89%
C: 0.65%
positive chmp
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.